BioInvent International AB

About Us

BioInvent International AB (OMXS: BINV) is a clinical stage company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapies, with four programs in clinical development. The Company’s validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company’s own clinical development pipeline or for additional licensing and partnering. The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company’s fully integrated manufacturing unit. More information is available at www.bioinvent.com.

Contacts

BIOINVENT
Sölvegatan 41 223 70 LUND
+46 46 286 85 50
+46 46 211 08 06
http://www.bioinvent.com
info@bioinvent.com

Quotes

FDA approval of the Phase I/IIa study of BI-1808 is another important milestone for BioInvent as we continue to broaden our exciting pipeline of anti-cancer antibodies. TNFR2 is increasingly attracting interest as revealed by the recent deals in the field. The development of BI-1808 is supported by an impressive set of preclinical data and is one of three BioInvent lead candidates in clinical development.

Martin Welschof, CEO BioInvent International

The data on BI-1607 are very exciting and provide proof-of-concept of its ability to enhance anti-cancer immunity, illustrated by its ability to boost activity and overcome resistance to CTLA-4-based therapy. We are looking forward to advancing BI-1607 into clinical development and expect to submit a clinical trial application during H2 2021. It will be BioInvent’s fourth drug candidate in clinical development, further demonstrating the strength and productivity of our technology platform.

Martin Welschof, CEO

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

BioInvent Interim Report 1 January – 30 September 2014

Thu, Oct 23, 2014 08:40 CET

Additional milestone payment and progress in prioritised projectsThird quarter 2014, July – September · Net sales for July – September 2014 amounted to SEK 11 (7.8) million. · Earnings after tax for July – September 2014: SEK -10 (-15) million. · Earnings after tax per share for July – September before and after dilution: SEK -0.09 (-0.19). · Cash flow from current operations and investment activities for July – September 2014: SEK -3.9 (-19) million. Nine-month report 2014, January – September · Net sales for January – September 2014 amounted to SEK 45 (32) million.

There are no items matching the current filter

There are no more items matching the current filter

Share

About Us

Contacts

Quotes

BioInvent Interim Report 1 January – 30 September 2014

Subscribe